Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: A phase 1/2 trial

The Lancet Oncology

Volumn 15, Issue 13, 2014, Pages 1451-1459

  Kennedy, Glen ^a,b   Varelias, Antiopi ^a   Vuckovic, Slavica ^a   Le Texier, Laetitia ^a   Gartlan, Kate H ^a   Zhang, Ping ^a   Thomas, Gethin ^c   Anderson, Lisa ^c   Boyle, Glen ^a   Cloonan, Nicole ^a   Leach, Justine ^a,b   Sturgeon, Elise ^a,b   Avery, Judy ^a,b   Olver, Stuart D ^a   Lor, Mary ^a   Misra, Ashish K ^b   Hutchins, Cheryl ^b   Morton, A James ^b   Durrant, Simon TS ^b   Subramoniapillai, Elango ^b   Butler, Jason P ^b   Curley, Cameron I ^b   MacDonald, Kelli P A ^a   Tey, Siok Keen ^a,b   Hill, Geoffrey R ^a,b   more..

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LIVER ENZYME; MELPHALAN; METHOTREXATE; STAT3 PROTEIN; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPERGILLOSIS; AUSTRALIA; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DONOR SELECTION; DRUG DOSE REDUCTION; ENGRAFTMENT; FAINTNESS; FEMALE; GASTROINTESTINAL TRACT; GRAFT VERSUS HOST REACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; INCIDENCE; LIVER TOXICITY; LUNG DIFFUSION CAPACITY; LUNG EDEMA; LUNG HEMORRHAGE; LYMPHOPROLIFERATIVE DISEASE; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NAUSEA; NONMYELOABLATIVE CONDITIONING; ORAL MUCOSITIS; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN SECRETION; RADIATION DOSE; REINFECTION; SKIN; TYPHLITIS; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING; VEIN OCCLUSION; VIRUS INFECTION; WHOLE BODY RADIATION; ADOLESCENT; ALLOTRANSPLANTATION; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84925228691     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71017-4     Document Type: Article

References (30)

1. Markey KA, MacDonald KP, Hill GR The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood 2014, 124:354-362.
2. Antin JH, Weisdorf D, Neuberg D, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002, 100:3479-3482.
3. Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
4. Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009, 114:891-900.
5. Tawara I, Koyama M, Liu C, et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res 2011, 17:77-88.
6. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011, 1813:878-888.
7. Serody JS, Hill GR The IL-17 differentiation pathway and its role in transplant outcome. Biol Blood Marrow Transplant 2012, 18:S56-S61.
8. Singh JA, Beg S, Lopez-Olivo MA Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2011, 38:10-20.
9. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
10. Klein JP, Rizzo JD, Zhang MJ, Keiding N Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: regression modeling. Bone Marrow Transplant 2001, 28:1001-1011.
11. Du P, Kibbe WA, Lin SM lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008, 24:1547-1548.
12. Simon R, Lam A, Ming-Chung L, Ngan M, Menenzes S, Zhao Y Analysis of gene expression data using BRB-array tools. Cancer Inform 2007, 3:11-17.
13. Duan R, Leo P, Bradbury L, Brown MA, Thomas G Gene expression profiling reveals a downregulation in immune-associated genes in patients with AS. Ann Rheum Dis 2010, 69:1724-1729.
14. Lin SM, Du P, Huber W, Kibbe WA Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 2008, 36:e11.
15. Workman C, Jensen LJ, Jarmer H, et al. A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol 2002, 3. research0048.
16. Morton J, Hutchins C, Durrant S Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001, 98:3186-3191.
17. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative G.
18. Hill GR, Kuns RD, Raffelt NC, et al. SOCS3 regulates graft-versus-host disease. Blood 2010, 116:287-296.
19. Jankovic D, Ganesan J, Bscheider M, et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med 2013, 210:1899-1910.
20. Seillet C, Belz GT Terminal differentiation of dendritic cells. Adv Immunol 2013, 120:185-210.
21. Springer TA Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
22. Lou Y, Liu S The TIPE (TNFAIP8) family in inflammation, immunity, and cancer. Mol Immunol 2011, 49:4-7.
23. Holler E, Kolb HJ, Mittermueller J, et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor a (TNFa) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFa (MAK 195F). Blood 1995, 86:890-899.
24. Hill GR, Teshima T, Gerbita A, et al. Differential roles of IL-1 and TNFa on graft-versus-host disease and graft-versus leukemia. J Clin Invest 1999, 104:459-467.
25. Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008, 111:2470-2475.
26. Kennedy GA, Butler J, Western R, Morton J, Durrant S, Hill GR Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 2006, 37:1143-1147.
27. Robb RJ, Hill GR The interferon-dependent orchestration of innate and adaptive immunity after transplantation. Blood 2012, 119:5351-5358.
28. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011, 117:3214-3219.
29. Hill GR, Olver SD, Kuns RD, et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 2010, 116:819-828.
30. Srinivasan M, Flynn R, Price A, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 2012, 119:1570-1580.